RESEARCH

Open Access

Drug prescription patterns and compliance with WHO and beers criteria in older patients



Mahan Malekzadeh¹, Yousef Khadivi², Seyed Mojtaba Sohrevardi^{3,4} and Golnaz Afzal^{3*}

Abstract

Background As the population ages, the prevalence of chronic diseases increases, leading to greater reliance on multiple medications that are conducted to increase the risk of adverse drug reactions (ADR) that may cause higher morbidity and mortality rates. This study aims to evaluate medication prescribing patterns in the older adults and assess compliance with the World Health Organization (WHO) guidelines and Beers Criteria.

Methods A cross-sectional study was conducted over six months in 2022, collecting prescriptions for patients aged 65 and above from a 24-hour community pharmacy in Iran. The prescriptions were analyzed according to the WHO prescribing guidelines, including the mean number of prescribed drugs, the number of injectable drugs and antibiotics per prescription, and also the prescription of drugs with generic names and from the list of Essential Drug List (EDL). In addition, the prescriptions were assessed according to the Beers Criteria for the frequency of prescription of potentially inappropriate medications (PIMs). Also, polypharmacy, which is defined as the prescription of more than five drugs per prescription, has been investigated based on the number of drugs prescribed per prescription.

Results 1,053 older patient prescriptions were assessed, whose average age was 72.3 ± 6.7 years, with 36.2% of prescriptions involving polypharmacy (five or more drugs). The most frequent medical discipline of prescribers was general practice (30.3%). The average number of drugs per prescription was 4.1 ± 2.1 , which exceeded the WHO recommendation. Additionally, 47.3% of prescriptions contained at least one PIM according to the Beers Criteria, with non-steroidal anti-inflammatory drugs (NSAIDs) being the most common (17.9%). The relative frequency of injectable drugs and antibiotics used per prescription was 20.8 and 18.9%, respectively, while 7.6% of prescriptions did not use generic names.

Conclusions The study highlights concern about levels of polypharmacy and PIM use in older patients. While the low rate of antibiotic prescribing and relatively high use of generic drugs indicate some positive adherence to WHO guidelines, the frequent prescription of PIMs and the high average number of drugs per prescription point to substantial room for improvement.

Keywords Beers Criteria, Potentially inappropriate medications, Geriatric, Drug prescriptions, Polypharmacy

*Correspondence: Golnaz Afzal dr.golnaz.afzal@gmail.com ¹Student Research Committee, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ²Metabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
³Department of Clinical Pharmacy, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
⁴Stroke Prevention and Atherosclerosis Research Centre, University of Western Ontario, London, Canada



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Background

According to estimates by the United Nations Population Division, the global population of individuals aged 60 and older is projected to reach approximately 2 billion by 2050, with more than one billion comprising those aged 70 to 75 [1]. As life expectancy rises, the definitions of health and wellness in late life have evolved. Heart disease, cancer, and stroke are now the leading causes of death among older adults, while deaths from infections have decreased. Older adults often suffer from high rates of chronic diseases, with 80% having at least one and 50% having at least two chronic conditions [2]. Due to the prevalence rate of various diseases among the old adults, medications are frequently used to manage disease progression [3]. However, organ damage and physiological changes in the older patients can alter pharmacokinetics and pharmacodynamics, increasing the risk of adverse drug reactions (ADR), and the use of potentially inappropriate medications (PIMs) that leading to higher mortality rates [4-6]. PIMs may involve inappropriate dosages or durations of drug administration, drug-drug, and drug-disease interactions [6]. These issues are widespread among older populations across different healthcare systems and are linked to increased risks of ADRs, additional medical costs, inappropriate use of healthcare resources, frequent falls, and mortality [7-10]. Approximately 20-30% of all hospital admissions in older adults are estimated to be related to PIMs, and up to 10% of them can be life-threatening or fatal [11-13].

The utilization of multiple medications known as polypharmacy is prevalent among older adults with multimorbidity, as one or more medications adults may be utilized to manage different illnesses [14]. Unfortunately, as the use of multiple medications escalates, the likelihood of adverse health outcomes, such as elevated healthcare expenses, drug interactions and ADRs, medication non-adherence, decreased functional capacity, and geriatric syndromes, increase [15, 16]. These outcomes can result from various factors, including drug-drug and drug-disease interactions. Furthermore, the likelihood of side effects and harm also rise in concordance with the number of medications [17]. Hence, reducing unnecessary medications and simplifying drug regimens are crucial strategies to improve patient safety [18].

Drug interventions aim to optimize individual drug therapy, minimize risks associated with drug therapy, and ensure safety and cost-effectiveness [17]. Pharmacological interventions can be tailored based on the epidemiology of PIMs, with strategies such as specific health education and targeted interventions significantly reducing the incidence of PIMs in the older adults [19].

In Canada and the United States, criteria and guidelines have been developed to assess the quality of prescribing practices and appropriate use of medications in older adults. The Beers Criteria are the most widely used tool for identifying inappropriate medications in this population [20]. The Beers Criteria categorize drugs into five groups: (1) potentially inappropriate drugs, (2) drugs to be avoided in certain circumstances, (3) drugs to be used with caution, (4) drug-drug interactions, and (5) drugs requiring dose adjustments based on kidney function [21].

The World Health Organization (WHO) advocates the rational use of drugs, providing indicators for drug use indications, evaluating prescription patterns, and assessing drug-related services [22].

To evaluate prescription patterns in older adults, the Beers Criteria can be used in conjunction with the WHO standard prescription indicators [21]. Since the Beers Criteria introduction, numerous studies examined prescribing patterns compared to these guidelines. These studies have revealed that many medications prescribed to older adults are inappropriate, leading to significant complications, increased costs, higher mortality rates, and increased demand for medical services [23–25].

Prescription patterns reflect the proficiency of physicians in diagnosing diseases and selecting appropriate treatments for older patients [26]. This study aims to investigate drug prescription patterns in older adults, identify potentially inappropriate medications, and compare them with the Beers Criteria and WHO prescription indicators. This can help pinpoint areas for improvement and ultimately optimize drug therapy and the healthcare system in Iran.

Methods

Study design

In this retrospective cross-sectional study analyzed the prescription patterns of all patients aged 65 and above, irrespective of whether the prescriptions addressed acute or chronic conditions. These patients were referred to a designated pharmacy and insured through various health insurance providers, including the Social Security Organization, Iran Health Insurance Organization, Armed Forces Medical Services Insurance Organization, and Institutional Health Insurance Funds. All data were extracted from the pharmacy's database, which registered prescriptions issued by hospital physicians and/ or private practitioners containing at least one medication. The study was conducted over a six-month period from October 2021 to March 2022 and was based in a 24-hour community pharmacy located in Yazd City, Iran. This pharmacy was selected as the representative site due to four key criteria: convenient geographical access for patients, extended working hours, the most comprehensive drug portfolio in the city, and a high concentration of doctors in the pharmacy's vicinity.

Data collection

All prescriptions that registered in the selected pharmacy prescription registration system reviewed during a six months interval regarding to insured covered patients aged over 65 years (based on the defined age of older adults by Beers Criteria) that their prescriptions containing at least one medication item (non-prescription, prescription, supplement, or herbal).

Based on a researcher-made data collection form, data gathering was performed. This form included demographic characteristics of the patients, such as age and sex, as well as details about the prescribing physician, including their classification as a general practitioner or specialist, and their specific area of specialization. Additionally, data were collected about the drugs prescribed in the prescription, based on two checklists: the WHO's standards and the Beer criteria [21, 22]. By using the WHO's checklist, the appropriateness of prescriptions by considering the total number of drugs prescribed, the use of generic names, injectable dosage forms, inclusion of drugs from the essential drug list (EDL), and the number of antibiotics prescribed, were assessed. By using the Beer criteria the prescription pattern was evaluated by checking for PIMs prescribed in general, as well as any types of PIMs, including the number, dosage, and dosage form of them (supplementary file) [27].

Ethical approval

This research was conducted with the approval of the Research Ethics Committee of Shahid Sadoughi University of Medical Sciences, as the code IR.SSU.MEDI-CINE.REC.1400.163. The committee confirmed that the research adhered to the ethical principles outlined in the 1964 Declaration of Helsinki and its subsequent amendments. Since the data collection relied exclusively on the

 Table 1
 Demographic characteristics of patients whom prescriptions collected

Criteria	Frequen- cy (%)
Gender	
Male	544 (51.7)
Female	509 (48.3)
Age distribution	
65–74	730 (69.3)
75–84	246 (23.4)
85–94	76 (7.2)
>= 95	1 (0.1)
Insurance coverage organization	
Armed Forces Medical Services Insurance Organization	272 (25.8)
Institutional Health Insurance Funds	497 (47.2)
Iran Health Insurance Organization	68 (6.5)
Social Security Organization	216 (20.5)
Sum	1,053 (100)

pharmacy's database and did not involve direct patient interaction, the requirement for informed consent was formally waived by the Research Ethics Committee of Shahid Sadoughi University of Medical Sciences. A certificate of data confidentiality and non-disclosure of patient information was obtained from the researcher. Furthermore, the study involved the participation of the pharmacy's pharmacist, with all necessary permissions obtained, and it was supervised by a clinical pharmacist faculty member.

Examining the prescription pattern

The prescription patterns were initially compared with the WHO's standard prescription pattern. The standard prescribing indicators include (1) an average of ≤ 3 drugs per prescription, (2) 100% use of generic names for prescribed drugs, (3) antibiotics constituting no more than 30% of medicines prescribed, (4) injectable drugs ranging from 10%, and (5) 100% availability of prescribed drugs on the Essential Drug List (EDL) [22].

PIMs were determined based on the Beers Criteria of the American Geriatrics Society, version 2023 [21, 22]. The Beers Criteria divide the list of drugs to be avoided in older adults into five categories, either for most cases or for specific diseases or conditions. Patients using any of the potentially inappropriate drugs listed in the Beers Criteria were assigned to the PIM use group, while those not using such drugs were assigned to the no PIM use group.

Data analyzing

All data related to prescription patterns were analyzed using IBM SPSS Statistics software, version 26. Quantitative data were reported as mean \pm standard deviation (SD), and qualitative data were reported using absolute frequencies and percentage. Pearson's correlation test and the Chi-square test were used to analyze variables. p < 0.05 was considered statistically significant in this study.

Results

In this study, 1,053 prescriptions were collected and examined during the 6-month study period. Of these prescriptions, 51.7% were belonged to female patients, and 48.3% to male patients. The patients' ages ranged from 65 to 97 years, with average of 72.3 ± 6.7 years (Table 1).

The most common categories of drugs were Antihypertensives (28.9%), Drugs for functional gastrointestinal, and acid related disorders (24.5%), and Anti-inflammatory and Antirheumatic products, non-steroids (22.3%) (Fig. 1).



Fig. 1 Distribution of drug classifications in collected prescriptions

Prescription patterns

General practitioners (GPs) accounted for the highest percentage of prescriptions (30.3%), followed by general internal medicine specialists (11.6%). The mean number of medications per prescription was 4.1 ± 2.1 , with a range of 1 to 13 medications. The median number of medications per prescription was 4.0. Polypharmacy was identified in 36.2% of the cases. Prescriptions which were prescribed by cardiologists included the highest average number of drugs prescribed per prescription (4.7 ± 2.7), while the lowest was observed in prescription which were prescribed by ophthalmologists (2.2 ± 1.2) (Table 2).

Injectable drugs were prescribed in 20.8% of the cases, with an average of 0.3 ± 0.7 injectable drugs per prescription. Antibiotic prescribing was relatively low, with oral antibiotics absent in 85.3% of prescriptions and injectable antibiotics absent in 95.4%. Furthermore, topical antibiotics were prescribed in even smaller amounts, with 99.4% of prescriptions excluding them Consequently, the mean number of antibiotics per prescription was 0.23 ± 0.5 . At least one antibiotic (oral, topical, or injectable) was included in only 18.9% of prescriptions, which is below the WHO's recommended indicator of 30%. In addition, 7.6% of the prescriptions did not include generic drugs (Table 3).

Potentially inappropriate medications (PIMs)

Out of the 1,053 prescriptions, 498 (47.3%) contained at least one PIM according to the Beers Criteria. The highest frequency of PIM prescriptions was seen in the 65 to 74-year age group, which accounted for 68.1% of the PIM-containing prescriptions. No statistically significant relationship was observed between the prescription of PIM and age of patients (p = 0.770). Most prescriptions with PIMs included only one PIMs (66.3%); however, 33.7% of prescriptions included up to six PIMs. The highest percentage of PIM were prescribed by GPs and surgeons (e.g. neurosurgery, general surgery, etc.), and on the other hand, the least amounts of PIM were prescribed by psychiatrists and Pain management fellowship Anesthesiologist. By using the chi-square test, it revealed that there is no significant relation between PIM prescription and different physician specialty (p = 0.897) (Table 4).

Table 5 shows the frequency and percentage of PIM drugs prescribed according to the Beers Criteria in the collected prescriptions. The most frequently prescribed PIMs were non-COX-2-selective oral NSAIDs, accounting for 219 instances (20.8%), followed by cardiovascular and antithrombotic agents (12.2%) and proton pump inhibitors (10.8%). Benzodiazepines were prescribed in 10.4% of cases, and central alpha-agonists in 8.0%. Notably, no prescriptions for high-risk medications such as nitrofurantoin or amiodarone were identified.

Physician specialty		Numberof prescriptions (%)	Mean number of drugs prescribed per prescription (mean±SD)	Minimum and maximum number of drugs prescribed per prescription
General Practitioner		319 (30.3)	4.3±2.2	1–13
Cardiology		81 (7.7)	4.7±2.7	1-12
Dermatology		19 (1.8)	3.2±1.7	1–6
Emergency Medicine		15 (1.4)	3.3±1.3	1–6
Infectious Diseases		19 (1.8)	3.5±1.2	1–5
General Internal Medicine		122 (11.6)	4.6±2.1	1-11
Subspeciality in	Pneumatology	10 (0.9)	3.8±1.3	2–6
	Rheumatology	37 (3.5)	4.4 ± 1.5	2–10
	Gastroenterology	10 (0.9)	3.9±1.6	2–6
	Endocrinology and Metabolism	35 (3.3)	4.2±2.0	1–8
Neurology		70 (6.6)	3.9±1.7	1–9
Obstetrics and Gynecology		11 (1.0)	4.2±1.9	1–7
Ophthalmology		78 (7.4)	2.2±1.2	1–9
Orthopedics		51 (4.8)	4.2±1.9	1-12
Pain management fellowship Anesthesiologist		5 (0.5)	3.4±2.5	1–7
Psychiatry		3 (0.3)	3.3±1.5	2–5
Surgery (e.g. Neurosurgery, General Surgery, etc.)		131 (12.4)	4.4±2.0	1-11
Urology		37 (3.5)	3.3 ± 1.0	2–5
Total		1,053 (100)	4.1±2.1	1–13

Table 2 Distribution of prescriptions and average number of drugs by physician specialty

Table 3 Compliance of prescription patterns with the WHO prescription guidelines for older patients

WHO Criteria [22]	Frequency (%) of 1,053 prescriptions
Number of drugs per prescription	
Mean (\pm SD) number of drugs per prescription	4.1 (2.1)
The range (minimum-maximum) of the number of drugs per prescription	1–13
Prescription with generic name	
The number of prescriptions without generic drugs	80 (7.6)
Mean (\pm SD) generic drugs prescribed per prescription	2.6 (1.6)
Range (minimum-maximum) of generic drugs prescribed per prescription	0–12
Administration of injectable drugs	
The number of prescriptions without injectable drugs	834 (79.2)
Mean (±SD) injectable drugs per prescription	0.3 (0.7)
Range (minimum-maximum) of injectable drugs prescribed per prescription	0–5
Prescribing antibiotics	
The number of prescriptions without	
Any antibiotics dosage form	854 (81.1)
Oral antibiotics dosage form	898 (85.3)
Injectable antibiotics dosage form	1005 (95.4)
Topical antibiotics dosage form	1047 (99.4)
Mean (\pm SD) antibiotics prescribed per prescription	0.2 (0.5)
Prescribing from the EDL list	
Mean (\pm SD) drugs prescribed from the EDL list per prescription	2.7 (1.6)
The range (minimum-maximum) of drugs prescribed from the EDL list per prescription	0–10

EDL: Essential drug list; SD: Standard Deviation

Discussion

This study reveals an examination of prescribing patterns within a 24-hour community pharmacy in Yazd, Iran, over a six-month period, with a particular emphasis on older patients. The findings reveal both positive trends and areas of concern, especially regarding adherence to WHO prescription guidelines, the frequency of polypharmacy, and the usage of PIMs in this vulnerable population [21, 22, 28].

Overall, the study demonstrated that the average number of drugs per prescription exceeded the WHO's recommended maximum of three. Generic prescribing was

Table 4 The frequency distribution of PIM prescription in order to the age of patients and specialty of physician

Criterion		Frequency (%)	<i>p</i> value
Number of Prescribed PIM per pre	escription		
1		330 (66.3)	Not indicated
2		124 (24.9)	
3		35 (7.0)	
4		8 (1.6)	
5		0 (0.0)	
6		1 (0.2)	
Prescribing PIM across different a	age ranges (years)		
65–74		339 (68.1)	0.770*
75–84		129 (25.9)	
85–94		30 (6.0)	
>= 95		0 (0.0)	
Physician specialty			
General Practitioner		150 (30.1)	0.897**
Cardiology		38 (7.6)	
Dermatology		7 (1.4)	
Emergency Medicine		7 (1.4)	
Infectious Diseases		8 (1.6)	
General Internal Medicine		60 (12.0)	
Subspeciality in	Pneumatology	3 (0.6)	
	Rheumatology	15 (3.0)	
	Gastroenterology	5 (1.0)	
	Endocrinology and Metabolism	16 (3.2)	
Neurology		36 (7.2)	
Obstetrics and Gynecology		6 (1.2)	
Ophthalmology		36 (7.2)	
Orthopedics		26 (5.2)	
Pain management fellowship Anesthesiologist		0 (0.0)	
Psychiatry		2 (0.4)	
Surgery (e.g. Neurosurgery, General Surgery, etc.)		67 (13.5)	
Urology		16 (3.2)	
Sum		498 (100)	

PIM: potentially inappropriate medications

*Pearson's correlation test, ** Chi-square test

reasonably high, and a small percentage of prescriptions included brand-name prescriptions. However, according to the WHO guideline, which has stated that 100% of the drugs prescribed in the prescriptions should be with generic names, it has not been able to fully comply. According to WHO standards, the use of injectable drugs and antibiotics in prescriptions is limited to a maximum of 10 and 30%, respectively, and in this study, the administration of injectable drugs and antibiotics was within the acceptable range of control [22]. Nevertheless, the high rate of PIM prescribing, particularly in the 65–74 age group, suggests the need for more cautious prescribing practices to reduce the risk of ADRs.

Prescription patterns and the frequency of polypharmacy

While polypharmacy is sometimes unavoidable, it heightens the risk of adverse reactions, drug interactions, and medication non-adherence, risks that are exacerbated in older adults due to age-related physiological changes [15].

The study's finding of an average of 4.1 drugs per prescription highlights a substantial prevalence of polypharmacy, with 36.2% of prescriptions containing multiple drugs. This aligns with similar study in comparable settings, where older patients' complex medical needs often necessitate multiple medications [29].

The role of GPs, who issued 30.3% of prescriptions, is particularly significant. GPs are often the primary care providers for older patients, managing a wide range of health issues [30]. The relatively higher frequency of drug prescribing by GPs may reflect a more reactive approach to healthcare, where symptoms are treated with additional medications which need additional attention to audit of GP's clinical approach, and encourage them to recommend the non-pharmacological interventions [31].

Table 5 The frequency distribution of prescribed PIM based on Beers Criteria [21]

Antibistamines >8 (5.3) Pringenetitor antibitamines >8 (5.3) Anti-infective 0.00 Nitsduration 0.00 Cardiovascular and Antibinambotic 0.00 Angin flot cardiovascular indication 0.00 Warfarin 128 (12.2) Physicoscular and Antibinambotic 0.00 Non-salective peripheoral lipho-1 blockers 0.00 Docazonin 0.00 Principant 0.00 Non-salective peripheoral lipho-1 blockers 0.00 Cardine 0.00 Tracasin 0.00 Pracasin 0.00 Pracasin 0.00 Antibactione 0.00 Dionedarone 0.00 Bertitopherodari direnegic activity Trithocypheroldy Trithocypheroldy 0.00 Trithocypher	Potentially Inappropriate Medications	Frequency (%)
Pre-generation arthiteatminesS8 (5.)Nitrofurantoin0.00Anthinfactive0.00Confurnation and Anthinombotic0.00Agarin fire callocascular and Anthinombotic0.00Daystantin1.84 (12.2)Waterotaban0.00Dipyratamole0.00Daystantin1.84 (12.2)Davarasin0.00Pascasin0.00Pascasin0.00Pascasin0.00Pascasin0.00Pascasin0.00Pascasin0.00Pascasin0.00Pascasin0.00Pascasin0.00Pascasin0.00Pascasin0.00Pascasin0.00Pascasin0.00Pascasin0.00Pascasin0.00Darastantinonin0.00Darastantinonin0.00Darastantinonin appertunition0.00Darastantinonin appertunition0.00Thrichear Earnattic Infolmention appertunition0.00Thrichear Earnattic Infolmention appertunition0.00Thrichear Earnattic Infolmention appertunition0.00Antipactonic0.00Thrichear Earnattic Infolmention0.00Thrichear Earnattic Infolmention0.00Thrichear Earnattic Infolmention0.00Thrichear Earnattic Infolmention0.00Thrichear Earnattic Infolmention0.00Thrichear Earnattic Infolmention0.00Thrichear Earnattic Infolmention0.00Datastanti	Antihistamines	
AddiancianAddiancian(0.0)Nitofurancian and Antithrombotic(0.0)Asprin (for cardiovascular indication)0.00)Asprin (for cardiovascular indication)0.00)Quardiant(0.0)Nardiant0.00)Riversotahan0.00Oppridamole0.00Descrotin0.00Pracasin0.00Trecazoin0.00Trecazoin0.00Antidacrone0.00Donectorin0.00Antidacrone0.00Donectorine0.00Donectorine0.00Donectorine0.00Donectorine0.00Donectorine0.00Donectorine0.00Donectorine0.00Donectorine0.00Donectorine0.00Donectorine0.00Antipatrixensity strong anticholinergic activity10Trictory phonectorine0.00Antipatrixensity and acticholinergic activity10Antipatrixensity and actic	First-generation antihistamines	58 (5.5)
Nuclairation0.000Cardiovascular and Aththomatic0.000Cardiovascular and Aththomatic0.000Aprilin for cardiovascular indication128.12.2.0Waronaban128.12.2.0Diportal andio128.12.2.0Diportal andio128.12.2.0Diportal andio128.12.2.0Diportal andio128.12.2.0Diportal andio128.12.0Divacción0.00.0Pravasin0.00.0Pravasin0.00.0Frazacin0.00.0Cardial dipole agonais0.00.0Cardial dipole agonais0.00.0Cardial dipole agonais0.00.0Cardial dipole agonais0.00.0Dienadarone0.00.0Dienadarone0.00.0Dienadarone0.00.0Dienadarone0.00.0Dienadarone0.00.0Dienadarone0.00.0Dienadarone0.00.0Dienadarone0.00.0Dienadarone0.00.0Dienadarone0.00.0Dienadarone0.00.0Antipatrisonia agents with strong anticholinegic activity0.00.0Antipatrisonia agents with strong acticholinegic activity0.00.0 <td>Anti-infective</td> <td></td>	Anti-infective	
Cardiovascular natication)0 (0.0Apprin (fior cardiovascular natication)0 (0.0Apprin (fior cardiovascular natication)0 (0.0Narfarin0 (0.0Nitrophole0 (0.0Dovazozin0 (0.0Prazozin0 (0.0Terzozin0 (0.0Terzozin0 (0.0Terzozin0 (0.0Terzozin0 (0.0Terzozin0 (0.0Concide cher apolisiz0 (0.0Concide cher apolisiz0 (0.0Dipoxin0 (0.0Dipoxin0 (0.0Dipoxin0 (0.0Dipoxin0 (0.0Dipoxin0 (0.0Dipoxin0 (0.0Dipoxin0 (0.0Dipoxin0 (0.0Dipoxin0 (0.0Antiderrous system0 (0.0Antidepressint strict/Asian discond generation0 (0.0Thicyclic antidepressints (TCAs)65 (6.2)Antiperiodic strikt and second generation0 (0.0Antiperiodic Strikt and second generation1 (0.1)Antiperiodic Strikt and second generation1 (0.1)Antiperiodic Strikt and second generation1 (0.1)Berzodiaczinies1 (0.1)Antiperiodic Strikt and second generation2 (2.2)Antiperiodic Strikt and second generation2 (2.2)Chindragepokick***2 (2.2)Chindragepokick***2 (2.2)Chindragepokick***2 (2.2)Chindragepokick***2 (2.2)Chindragepokick***2 (2.2)Chindragepokick***2 (2.	Nitrofurantoin	0 (0.0)
Appint for cardiovascular indication)0.00Warfarin128 (12.2)Warfarin0.00Dipyrilamole0.00Dipyrilamole0.00Non-selective griphent dipho-1 blockers0.00Tarazosin0.00Tarazosin0.00Tarazosin0.00Tarazosin0.00Tarazosin0.00Condine0.00Mindipine0.00Objection0.00Diportin0.00	Cardiovascular and Antithrombotic	
Weiralin128 (122)Nivaroakin0100Dipytilamole0100Dipytilamole0100Pazasin0100Pazasin0100Pazasin0100Clonidina44 (29)Nikelipina0100Diadorone0100Dionedianne0100Titypicitamitediopresants (TCA)65 (62)Antippicatolic (rain)0100Titypicatolic (rain)0100Titypicatolic (rain)0100Dianapine0100Olaraapine0101Dianapine25 (24)Chordiazpositie*25 (24)Chordiazpositie*25 (24)Chordiazpositie*26 (20)Diazpoin0100Diazpoin0100Diazpoin0100Diazpoin0100Diazpo	Aspirin (for cardiovascular indication)	0 (0.0)
Piveroxeban0 (0.0Dipyridamole0 (0.0)Dispridamole0 (0.0)Dispridamole0 (0.0)Teracosin0 (0.0)Teracosin0 (0.0)Teracosin0 (0.0)Teracosin0 (0.0)Central dipho-agorists0 (0.0)Central dipho-agorists0 (0.0)Niedprine0 (0.0)Oronedamone0 (0.0)Diporin0 (0.0)Tricyclic antidepresants (TCAs)0 (0.0)Antipactonian agents with strong anticholinergic activity0 (0.0)Tricyclic antidepresants (TCAs)0 (0.0)Antiporitopical0 (0.0)Antiporitopical0 (0.0)Antiporitopical0 (0.0)Antiporitopical0 (0.0)Resctropine (ana)0 (0.0)Antiporitopical0 (0.0)Antiporitopical0 (0.0)Resctropine (ana)0 (0.0)Antiporitopical0 (0.0)Resctropine (ana)0 (0.0)Diapapin0 (0.0)Charappine0 (0.0)Charappine0 (0.0)Charappine (ana)0 (0.0)Charappine (ana)0 (0.0)Charappine (ana)0 (0.0)	Warfarin	128 (12.2)
Dipyridamole0.0.0Non-selective periphean lapho-1 blockers0.0.0Pracosin0.0.0Pracosin0.0.0Trazosin0.0.0Central olpho-agonists0.0.0Concider0.0.0Miledipine0.0.0Amindersons0.0.0Diposin0.0.0Diposin0.0.0Diposin0.0.0Diposin0.0.0Diposin0.0.0Diposin0.0.0Diposin0.0.0Diposin0.0.0Diposin0.0.0Diposin0.0.0Diposin0.0.0Diposin0.0.0Diposin0.0.0Diposin0.0.0Antipersonsmits with strong anticholinergic activity55 (2)Maripersonsmits strong anticholinergic activity55 (2)Benztropine (oral)0.0.0Threpsphericity0.0.0Threpsphericity0.0.0Threpsphericity0.0.0Threpsphericity0.0.0Threpsphericity0.0.0Threpsphericity0.0.0Charazolne0.0.0Olanzapine25 (24)Charazopani16 (1.5)Prenobatibal0.0.0Mitaraolam0.0.0Obazapine0.0.0Charazopani0.0.0Charazopani0.0.0Charazopani0.0.0Charazopani0.0.0Charazopani0.0.0Charazopani0.0.0Charazopani0.0.0Charazopani<	Rivaroxaban	0 (0.0)
Non-selective peripheral alpha-1 blockers 00.00) Prazosin 00.00) Terzosin 41.39) Central alpha-agonists 00.00) Central alpha-agonists 00.00) Central alpha-agonists 00.00) Considine 04.079 Nited pine 0.000 Dingxin 0.000 Dingxin 0.000 Dingxin 0.000 Dingxin 65.62) Antipagenesiants with strong anticholinergic activity 0.000 Exertopine (oral) 0.000 Thrityschic antidepressants (CEA) 65.62) Antipagenesion 60.05 Halapentidol 30.31 Obrazpine 60.05 Halapentidol 30.33 Obrazpine 70.07 Barbiturates 70.07 Barbiturates 70.07 Barbiturates 20.02 Charapependice 20.02 Charapepan 60.01 Obrazpine 20.02 Obrazepan 20.02	Dipyridamole	0 (0.0)
Descarsion0 (0.0)Practs0 (0.0)Fracts41 (3.9)Conidine41 (3.9)Kiedipine0 (0.0)Amilacianone0 (0.0)Dononclarone0 (0.0)Digoxin1 (0.1)Conidinerous system1 (0.1)Antidepressants (TCAs)65 (6.2)Antipersion subtristing anticholinergic activity1 (0.1)Friegolic antidepressants (TCAs)65 (6.2)Antipersion agents with strong anticholinergic activity0 (0.0)Thispechicantidepressants (TCAs)65 (6.2)Antipersion agents with strong anticholinergic activity1 (0.1)Antipersion agents with strong anticholinergic activity6 (0.6)Antipersion agents with strong anticholinergic activity6 (0.6)Hencyphenkyl1 (0.1)Antipersion agents with strong anticholinergic activity9 (0.9)Risperidone9 (0.9)Risperidone9 (0.9)Risperidone9 (0.9)Risperidone9 (0.9)Olarazpine2 (0.1)Quetapine2 (0.2)Chorditagepoxide*5 (5.4)Chorditagepoxide*5 (5.4)Chorditagepoxide*2 (0.2)Larazpam3 (0.3)Midazola0 (0.0)Nonbencodiazpines hypontics2 (0.2)Eutopers0 (0.0)Entropies with or without progestins0 (0.0)Strongers with or without progestins0 (0.0)Insuli (al type)2 (0.2)Descenter inhibitor2 (0.2)Descenter inhibitor	Non-selective peripheral alpha-1 blockers	
Pracesin0 (0.0)Terazosin41 (3.9)Clonidine84 (7.9)Niedpine0.0.0)Niedpine0.0.0)Dinodarone0.0.0)Digoxin0.0.0)Digoxin0.0.0Digoxin0.0.0Digoxin0.0.0Digoxin0.0.0Digoxin0.0.0Tricyclic antidepressants (TCAs)65 (6.2)Antipationsonian agents with strong anticholinergic activity0.0.0Berzotopine (oral)0.0.0Tricyclic antidepressants (TCAs)65 (6.2)Antipationsonian agents with strong anticholinergic activity0.0.0Berzotopine (oral)0.0.0Antipationsonian agents with strong anticholinergic activity0.0.0Berzotopine (oral)0.0.0Antipationsonian agents with strong anticholinergic activity0.0.0Berzotopine (oral)0.0.0Olarzapine0.0.0Antipatione9.0.9Bisperidon7.0.7Berzotolzepines10.1)Berzotolzepines10.1)Diazepan25 (2.4)Chardiazepaxide*26 (2.0)Chardiazepaxide*26 (2.0)Diazepan26 (2.0)Norhencodazepines hypotoles20.01Zolpidem20.02Endorer0.0.00Chardiazepaxide*0.0.00Diagenes hypotoles0.0.00Diagenes hypotoles0.0.00SufforyLines0.0.00Diagenes hypotoles0.0.00SufforyLines0.0.00 <t< td=""><td>Doxazosin</td><td>0 (0.0)</td></t<>	Doxazosin	0 (0.0)
Terazosin41 (39)Central aptra-agonistsKet (7)Nifedipline0 (0.0)Amiodarone0 (0.0)Diorondarone0 (0.0)Dioron1 (0.1)Central nervous system1 (0.1)Antidepressants with strong anticholinergic activity56 (a.2)Antidepressants with strong anticholinergic activity56 (a.2)Antipersonts with strong anticholinergic activity10 (0.0)Ticry clic antidepressants (TCA)65 (a.2)Antipersonts with strong anticholinergic activity10 (0.0)Ticry clic antidepressants (TCA)6 (b.6)Antipersonts with strong anticholinergic activity10 (0.0)Benztropine toral0 (0.0)Ticry clic antidepressants (TCA)6 (b.6)Antipersonts with strong anticholinergic activity6 (b.6)Halopentidol3 (b.3)Outerapine2 (0.2)Outerapine9 (b.9)Halopentidol3 (b.3)Outerapine2 (b.2)Outerapine2 (b.2)Chordrazepoxide*7 (5 (A)Chordrazepoxide*2 (b.2)Lorazopam2 (b.2)Lorazopam2 (b.2)Nantoeradiazopines hypontics2 (b.2)Zolpines9 (b.0)Nantoeradiazopines hypontics2 (b.2)Lorazopam0 (b.0)Nantoeradiazopines hypontics2 (b.2)Lorazopam0 (b.0)Nantoeradiazopines hypontics0 (b.0)Extrogens with or without progestins0 (b.0)Indicatan0 (b.0)I	Prazosin	0 (0.0)
Central alpha-aganists Sector Clondine 84 (7.9) Nikelipine 0.00 Amiodarone 0.00 Digoxin 0.00 Digoxin 0.00 Trinocil carrone 0.00 Digoxin 0.00 Central hervous system 0.00 Antigapersonts with strong anticholinergic activity 56.2 Antipatrisonian agents with strong anticholinergic activity 61.6.2 Trinocil carropine (rola) 0.00 Antipatrisonian agents with strong anticholinergic activity 0.00 Benztropine (rola) 0.00 Antipatropine (rola) 0.00 Antipatropine (rola) 0.00 Antipatropine (rola) 0.00 Obscriptionelidy 15.1.4 Antipatropine (rola) 0.00 Olanzapine 12.(1.1) Quetipine 9.0.9 Risperidone 7.0.7 Barbitruates 7.0.7 Pherobarbital 5.6.4 Clonazepan 26.24 Chordiazepoxide* 7.6.5.4	Terazosin	41 (3.9)
Clonidine84 (7.9)Nifedipine0.00Amiodarone0.00Drone darone0.00Digoxin10.1Beratrone0.00Antidparseants with strong anticholinergic activity65 (6.2)Antiparseants with strong anticholinergic activity65 (6.2)Antiparseants with strong anticholinergic activity60.00Tric yolic antidepressants (TCA)65 (6.2)Antiparseants with strong anticholinergic activity60.00This yolic first and second generation60.00Antiparseants with strong anticholinergic activity60.00This yolic first and second generation60.00Antiparseants60.00Haloperidol30.33Olanzapine70.7Borbitures70.7Borbitures70.7Borbitures70.7Appracodiczepines70.7Appracodiczepines70.7Appracodiczepines70.7Appracodiczepines70.7Appracodiczepines70.7Appracodiczepines70.7Appracodiczepines70.7Nonberacodiczepines hypnotics70.7Zolarden0.00Ocarapara0.00Ocarapara0.00Constrone0.00Borbitures0.00SulfonyLines0.00Constrone0.00Discopers with or without progestins0.00Discopers with or without progestins0.00Discopers with or without progestins0.00Discopers with or without p	Central alpha-agonists	
Nifedipine0 (0.0)Arrilogine0 (0.0)Donoedarone0 (0.0)Digoxin1 (0.1)Central nervous system1Antidepressants with strong anticholinergic activity65 (6.2)Antidepressants (TCAs)65 (6.2)Antidepressants (TCAs)0 (0.0)Tincyclic antidepressants (TCAs)0 (0.0)Tincyclic antidepressants (TCAs)65 (6.2)Antidepressants (TCAs)0 (0.0)Tincyclic antidepressants (TCAs)0 (0.0)Antipscychotics, First and second generation0 (0.0)Antipscychotics, First and second generation0 (0.0)Antipscychotics, First and second generation0 (0.0)Obacappine0 (0.0)Obacappine0 (0.0)Barbitruotes0 (0.0)Phenobarbital25 (2.4)Choracappan26 (2.4)Choracappan26 (2.4)Choracappan26 (2.4)Diazepanh0 (0.0)Obacappine0 (0.0)Obacappine hyprotics0 (0.0)Zolopidem0 (0.0)Nonbenzodazpines hyprotics0 (0.0)Insulin (all types)0 (0.0)SulforyLinas0 (0.0)Nonbenzodazpines hyprotics0 (0.0)Insulin (all types)0 (0.0)SulforyLinas0 (0.0)Descreter turbitors0 (0.0)Descretor turbitors0 (0.0)Descretor turbitors0 (0.0)Descretor turbitors0 (0.0)Descretor turbitors0 (0.0)Descretor turbitors0	Clonidine	84 (7 9)
Amicidance 0.00 Denealarone 0.00 Denealarone 0.00 Denealarone 0.00 Denealarone 0.00 Central nervous system 10.1 Antiderkinsonian agents with strong anticholinegic activity 65 (6.2) Antigerkinsonian agents with strong anticholinegic activity 0.00 Tritycyclic antichegressants (TCAs) 65 (6.2) Antigerkinsonian agents with strong anticholinegic activity 0.00 Benztropine (oral) 0.00 Tritycyphenidy1 0.00 Antiperkinschirts, first and second generation 6.06.6 Haloperido1 3.0.3 Olanzapine 9.09 Risperidone 2.0.2 Berbautates 9 Phenobarbital 1.0.1 Berbautates 2.0.2 Aprazohn 2.0.2 Chorazeparn 2.0.2 Diazeparn 2.0.2 Diazeparn 0.00 Okazeparn 0.00 Okazeparn 0.00 Sutifonylureas 0.00	Nifedinine	0 (0 0)
Anioacola 0.00 Digoxin 10.01 Central nervous system Anitoperssants with strong anticholinergic activity 65 (6.2) Anitoperssants with strong anticholinergic activity 65 (6.2) Anitoperssants with strong anticholinergic activity 60 (0.0) Trinecyclic anticlepressants (TCAs) 66 (6.2) Anitopersona agents with strong anticholinergic activity 00.00 Trinecyclic anticlepressants (TCAs) 66 (6.2) Anitopressants with strong anticholinergic activity 00.00 Trinecyclic antidepressants (TCAs) 60 (0.0) Anitopressants with strong anticholinergic activity 00.00 Barbatures 00.00 Barbatures 00.01 Barbatures 00.01 Barbatures 25 (2.4) Chordiazepoxide* 20 (0.2) Corazepam 20 (0	Amiodarone	0 (0.0)
Digosin 0 (0.0) Contraction 1 (0.1) Contract nervous system 1 (0.1) Antidepressants with strong anticholinergic activity 65 (6.2) Antiparkinsonian agents with strong anticholinergic activity 65 (6.2) Pertorpine (oral) 0 (0.0) Tritycic antidepressants (TCAs) 65 (6.2) Antiparkinsonian agents with strong anticholinergic activity 0 (0.0) Tritycic phenicly 15 (1.4) Antipsychotics, First and second generation 6 (0.6) Halopedidol 3 (0.3) Olanzapine 2 (1.1) Quetipine 9 (0.9) Risperidone 9 (0.9) Barbiturates 7 (0.7) Prenobarbital 10 (1) Bernzodiazepines 2 (2.4) Chordiazepaxide* 5 (5.4) Clonazepaxin 2 (0.2) Diazepaxin 3 (0.3) Midazolarn 2 (0.2) Loazepaxin 3 (0.3) Midazolarn 0 (0.0) Conzepaxin 9 (0.9) Sulponyluceas 0 (0.0) <td>Dronedarone</td> <td>0 (0.0)</td>	Dronedarone	0 (0.0)
Chypolic (****) Chrital nervous system ************************************	Digoxin	1 (0.1)
Anidepressions with strong anticholinergic activity Tricyclic antidepressants (TCAs) 65 (6.2) Anigarisissonian agents with strong anticholinergic activity Benztropine (oral) 0,000 Trihexyphenidyl 15 (1.4) Anigypressions with strong anticholinergic activity Benztropine (oral) 15 (1.4) Anigypressions with strong anticholinergic activity Trihexyphenidyl 15 (1.4) Anigypressions with strong anticholinergic activity Halpperide 30,03 Olanzapine 0,009 Risperidone 9,009 Risperidone 9,009 Risperidone 9,009 Risperidone 9,009 Risperidone 9,009 Risperidone 2,007 Barbiturates 10,007 Barbiturates 25 (2.4) Chordiazepoxide* 57 (5.4) Chordiazepoxide* 57 (5.4) Chorazepam 2,002 Diazepam 2,002 Nonzeepam 2,002 Nonzeepam 2,002 Extorgens hypnotics 2,020 Extorgens with or without progestins 0,000 Insulin (all types) 40 (3.8) Sulforylureas 2,019) Desicated thyroid 40 (3.0) Gastrottestinal Poton-ouroin inhibitors	Central nervous system	1 (0.1)
Tricyclic antidepressnis (TCA) 65 (6.2) Antiparkinsonian agents with strong anticholinergic activity 00.00 Benztropine (oral) 15 (1.4) Antiparkinsonian agents with strong anticholinergic activity 60.00 Inthesyphenidy 15 (1.4) Antiparkinsonian agents with strong anticholinergic activity 60.00 Benztopine 70.07 Quetlapine 70.07 Benztopine 70.07 Benztopine 70.07 Aprazolam 70.07 Chordiazepoxide* 75 (5.4) Clonazepam 70.00 Natazolan 70.00 Natoz	Antidepressants with strong anticholineraic activity	
Inspace integregation (1907) 0 (0.2) Antiparkinsoin agents with strong anticholinergic activity 0 (0.0) Trihesyphenidy 15 (1.4) Antiparkinsoin agents with strong anticholinergic activity 0 (0.0) Trihesyphenidy 6 (0.6) Antiparkinsoin agents with strong anticholinergic activity 3 (0.3) Olanzapine 9 (0.9) Risperidone 7 (0.7) Barbital 1 (0.1) Benzodiazepines 7 (5.4) Clonazepam 2 (0.2) Lorazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 0 (0.0) Iosactines hypnotics 2 (0.2) Zolpidem 2 (0.2)	Tricyclic antidepressants (TCAs)	65 (6 2)
Benzippine (oral) 0(0.0) Trihexyphenidyl 15 (1.4) Antipyschotics, First and second generation 6 (0.6) Haloperidol 3 (0.3) Olanzapine 12 (1.1) Quetiapine 9 (0.9) Risperidone 9 (0.9) Benztropine (oral) 12 (1.1) Quetiapine 9 (0.9) Bisperidone 9 (0.9) Barbitruates 10.1) Phenobarbital 10.1) Benzodiazepines 25 (2.4) Chlordiazepoxide* 25 (5.4) Clonazepam 2 (0.2) Lorazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 2 (0.2) Lorazepam 3 (0.3) Midazolam 0 (0.0) Okazepam 0 (0.0) Sulforniu (all types) 0 (0.0) Estrogens with or without progestins 0 (0.0) Insulin (all types) 20 (1.9) Sulfornylureas 20 (1.9) Desiccated thyroid 0 (0.0) Gatroline uninhibitor	Antinarkinsonian agents with strong anticholineraic activity	05 (0.2)
Close Close Tribacipane (stud) 15 (1.4) Antipischotics, First and second generation 6 (0.6) Haloperidol 3 (0.3) Olanzapine 12 (1.1) Quetiapine 9 (0.9) Risperidone 9 (0.9) Risperidone 9 (0.9) Barbiturates 7 (0.7) Phenobarbital 10 (1.1) Benzodiazepines 1 Alprazolam 25 (2.4) Chordiazepoxide* 57 (5.4) Clonazepam 2 (0.2) Lorazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 0 (0.0) Oxazepam 0 (0.0) Oxazepam 0 (0.0) Oxazepam 0 (0.0) Diazepan 2 (0.2) Lorazepam 0 (0.0) Oxazepam 0 (0.0) Diazepan 2 (0.2) Lorazepam 0 (0.0) Extoret bypontics 2 (0.2) Lorazepan 0 (0.0) Extoret bypontics 2 (0	Benztronine (oral)	0 (0 0)
Interspiration 6 (0.6) Antipsycholics, First and second generation 6 (0.6) Haloperidol 3 (0.3) Olanzapine 9 (0.9) Risperidone 7 (0.7) Barbiturates 7 (0.7) Phenobarbital 10.1 Benzodiazepines 10.1 Alprazolam 25 (2.4) Chlordiazepoxide* 57 (5.4) Clonazepam 16 (1.5) Diazepam 2 (0.2) Lorazepam 0 (0.0) Oxazepam 0 (0.0) Oxazepam 2 (0.2) Lorazepam 0 (0.0) Nobenzodiazepines hypnotics 2 (0.2) Zolpidem 0 (0.0) Oxazepam 0 (0.0) Nobenzodiazepines hypnotics 2 (0.2) Zolpidem suppontics 2 (0.2) Endocrime 0 (0.0) Insulin (all types) 0 (0.0) Sutfonylureas 0 (0.0) Desiccated thyroid 3 (7.3) Megestrol 0 (0.0) Gotrimetsind 0 (0.0) </td <td></td> <td>15 (1.4)</td>		15 (1.4)
Aripipazole 6 (0.6) Haloperidol 3 (0.3) Olanzapine 12 (1.1) Quetiapine 9 (0.9) Risperidone 7 (0.7) Barbiturates 1 Phenobarbital 1 (0.1) Benzodiazepines 1 Afipizazola 2 5 (2.4) Chlordiazepoxide* 57 (5.4) Clonazepam 16 (1.5) Diazepam 2 (0.2) Lorazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 2 (0.2) Lorazepam 2 (0.2) Lorazepam 0 (0.0) Oxazepam 0 (0.0) Oxazepam 0 (0.0) Korione 0 (0.0) Korione 0 (0.0) Estrogens with or without progestins 0 (0.0) Insulin (all types) 40 (3.8) Sulfonylureas 0 (1.9) Desiccated thyroid 0 (0.0) Gastrointestind 0 (0.0)	Antinsychotics First and second generation	15(1.7)
Haloperidol 3 (0.3) Olanzapine 12 (1.1) Quetiapine 9 (0.9) Risperidon 7 (0.7) Barbiturates 7 Phenobarbital 1 (0.1) Benzodiazepines 57 (5.4) Clonazepam 2 (0.2) Clonazepam 2 (0.2) Diazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 2 (0.2) Lorazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 0 (0.0) Nonbenzodiazepines hypnotics 2 (0.2) Zolpidem 2 (0.2) Insulin (all types) 2 (0.2) Nonbenzodiazepines hypnotics 0 (0.0) Suffonylureas 0 (0.0) Insulin (all types) 40 (3.8) Suffonylureas 2 (0.1) Desiccated thyroid 3 (7.3) Megestrol 0 (0.0) Growth hormone 0 (0.0) Goxtoritestind 7 (3.5)	Ariningazole	6 (0.6)
Alarpeina 5 (6.3) Olanzapine 12 (1.1) Quetipine 9 (0.9) Risperidone 7 (0.7) Barbiturates 7 Phenobarbital 10 (1) Benzodiazepines 7 Alprazolam 25 (2.4) Chlordiazepoxide* 57 (5.4) Clonazepam 16 (1.5) Diazepam 2 (0.2) Lorazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 2 (0.2) Lorazepam 2 (0.2) Lorazepam 0 (0.0) Oxazepam 0 (0.0) Oxazepam 2 (0.2) Indocrine 2 Androgens 0 (0.0) Estrogens with or without progestins 0 (0.0) Insulin (all types) 40 (3.8) Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Gortoritestinal 70.0)	Haloperidol	3 (0.3)
Quetiapine 9(09) Risperidone 7(07) Barbiturates 1 Phenobarbital 1 Barbotiturates 1 Alprazolarepines 1 Alprazolarepines 5 Chlordiazepoxide* 57 (5.4) Chorazepam 16 (1.5) Diazepam 2 (0.2) Lorazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 2 (0.2) Lorazepam 2 (0.2) Lorazepam 2 (0.2) Morazepam 0 (0.0) Oxazepam 0 (0.0) Oxazepam 2 (0.2) Zolpidem 2 (0.2) Endocrine 2 (0.2) Androgens 0 (0.0) Insulin (all types) 40 (3.8) Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Gortmestinal 9 (0.0) Potor-neumo inhibitors 0 (0.0)		12 (1 1)
Risperidone 7 (0.7) Barbiturates 7 (0.7) Phenobarbital 1 (0.1) Benzodiazepines 1 (0.1) Alprazolam 25 (2.4) Chlordiazepoxide* 57 (5.4) Clonazepam 16 (1.5) Diazepam 2 (0.2) Lorazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 0 (0.0) Oxazepam 0 (0.0) Oxazepam 2 (0.2) Endocrine 2 Androgens 0 (0.0) Estrogens with or without progestins 0 (0.0) Insulin (all types) 40 (3.8) Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Growth hormone 0 (0.0) Growth hormone 0 (0.0)		Q (0.9)
Barbiturates (6.1) Phenobarbital 1 (0.1) Benzodiazepines (10.1) Alprazolam 25 (2.4) Chlordiazepoxide* 57 (5.4) Clonazepan 16 (1.5) Diazepam 2 (0.2) Lorazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 7 (0.7) Nonbenzodiazepines hypnotics 7 (0.7) Zolpidem 2 (0.2) Endocrine 2 (0.0) Androgens 0 (0.0) Estrogens with or without progestins 0 (0.0) Insulin (all types) 40 (3.8) Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Gastrointestinal 0 (0.0)	Risperidone	7 (0.7)
Phenobarbital 1 (0.1) Benzodiazepines 25 (2.4) Alprazolam 25 (2.4) Chlordiazepoxide* 57 (5.4) Clonazepam 16 (1.5) Diazepam 2 (0.2) Lorazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 0 (0.0) Oxazepam 2 (0.2) Lorazepam 2 (0.2) Nohenzodiazepines hypnotics 2 (0.2) Zolpidem 2 (0.2) Nonbenzodiazepines hypnotics 2 (0.2) Zolpidem 0 (0.0) Estrogens with or without progestins 0 (0.0) Insulin (all types) 40 (3.8) Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Growth hormone 0 (0.0) Brotoritestinal 90 (0.0)	Rachiturates	7 (0.7)
IncludingInclusionInclusionBenzodiazepines25 (2.4)Alprazolam25 (2.4)Chordiazepoxide*7 (5.4)Clonazepam16 (1.5)Diazepam2 (0.2)Lorazepam3 (0.3)Midazolam0 (0.0)Oxazepam7 (0.7)Nonbenzodiazepines hypnotics7Zolpidem2 (0.2)Endocrine7Androgens0 (0.0)Estrogens with or without progestins0 (0.0)Insulin (all types)40 (3.8)Sulfonylureas20 (1.9)Desiccated thyroid37 (3.5)Megestrol0 (0.0)Growth hormone0 (0.0)Gastrointestinal0 (0.0)Proton-pump inhibitors0	Phenoharhital	1 (0 1)
Alprazolam 25 (2.4) Chlordiazepoxide* 57 (5.4) Clonazepam 16 (1.5) Diazepam 2 (0.2) Lorazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 7 (0.7) Nonbenzodiazepines hypnotics 7 (0.7) Zolpidem 2 (0.2) Endocrine 7 (0.7) Nonbenzodiazepines hypnotics 2 (0.2) Zolpidem 2 (0.2) Istrogens 0 (0.0) Estrogens with or without progestins 0 (0.0) Insulin (all types) 40 (3.8) Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Growth hormone 0 (0.0) Bastrointestinal 0 (0.0)	Renzodiazenines	1 (0.1)
Approxibility 25 (2.4) Chlordiazepoxide* 57 (5.4) Clonazepam 16 (1.5) Diazepam 2 (0.2) Lorazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 7 (0.7) Nonbenzodiazepines hypnotics 2 Zolpidem 2 (0.2) Endocrine 2 Androgens 0 (0.0) Insulin (all types) 40 (3.8) Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Growth hormone 0 (0.0) Forton-pump inhibitors 0 (0.0)	Alorazolam	25 (24)
Clinate park 57 (3.4) Clonazepark 16 (1.5) Diazepark 2 (0.2) Lorazepark 3 (0.3) Midazolark 0 (0.0) Oxazepark 7 (0.7) Nonbenzodiazepines hypnotics 2 (0.2) Zolpiderk 2 (0.2) Endocrine 2 (0.2) Androgens 0 (0.0) Estrogens with or without progestins 0 (0.0) Insulin (all types) 40 (3.8) Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Growth hormone 0 (0.0) Proton-pump inhibitors 0 (0.0)	Chlordiazenovida*	57 (5 <i>1</i>)
Diazepam10 (1.5)Diazepam2 (0.2)Lorazepam3 (0.3)Midazolam0 (0.0)Oxazepam7 (0.7)Nonbenzodiazepines hypnotics2 (0.2)Zolpidem2 (0.2)Endocrine0 (0.0)Estrogens0 (0.0)Insulin (all types)0 (0.0)Sulfonylureas0 (0.0)Desiccated thyroid37 (3.5)Megestrol0 (0.0)Growth hormone0 (0.0)Bastrointestinal0 (0.0)Proton-pump inhibitors0 (0.0)	Clonazenam	16 (1 5)
Lorazepam 3 (0.2) Lorazepam 3 (0.3) Midazolam 0 (0.0) Oxazepam 7 (0.7) Nonbenzodiazepines hypnotics 2 (0.2) Zolpidem 2 (0.2) Endocrine 0 (0.0) Androgens 0 (0.0) Estrogens with or without progestins 0 (0.0) Insulin (all types) 40 (3.8) Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Growth hormone 0 (0.0) Proton-pump inhibitors 0 (0.0)	Diazenam	2 (0 2)
Midazolam 0 (0.0) Oxazepam 7 (0.7) Nonbenzodiazepines hypnotics 2 (0.2) Endocrine 0 (0.0) Androgens 0 (0.0) Estrogens with or without progestins 0 (0.0) Insulin (all types) 0 (0.0) Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Growth hormone 0 (0.0)		3 (0.3)
Oxazepam 0 (0.0) Oxazepam 7 (0.7) Nonbenzodiazepines hypnotics 2 (0.2) Endocrine 0 (0.0) Androgens 0 (0.0) Estrogens with or without progestins 0 (0.0) Insulin (all types) 0 (0.0) Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Growth hormone 0 (0.0) Proton-pump inhibitors 0	Midazolam	0 (0.0)
Nonbenzodiazepines hypnotics 2 (0.2) Zolpidem 2 (0.2) Endocrine 0 (0.0) Androgens 0 (0.0) Estrogens with or without progestins 0 (0.0) Insulin (all types) 40 (3.8) Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Growth hormone 0 (0.0) Proton-pump inhibitors 0		7 (0.7)
Zolpidem2 (0.2)Endocrine0 (0.0)Androgens0 (0.0)Estrogens with or without progestins0 (0.0)Insulin (all types)40 (3.8)Sulfonylureas20 (1.9)Desiccated thyroid37 (3.5)Megestrol0 (0.0)Growth hormone0 (0.0)GastrointestinalProton-pump inhibitors	Nonhenzodiazenines hypnotics	7 (0.7)
Endocrine 0 (0.0) Androgens 0 (0.0) Estrogens with or without progestins 0 (0.0) Insulin (all types) 40 (3.8) Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Growth hormone 0 (0.0) Forton-pump inhibitors 0	Zolnidem	2 (0 2)
Androgens0 (0.0)Estrogens with or without progestins0 (0.0)Insulin (all types)40 (3.8)Sulfonylureas20 (1.9)Desiccated thyroid37 (3.5)Megestrol0 (0.0)Growth hormone0 (0.0)GastrointestinalProton-pump inhibitors	Endocrine	2 (0.2)
Nucley0 (0.0)Estrogens with or without progestins0 (0.0)Insulin (all types)40 (3.8)Sulfonylureas20 (1.9)Desiccated thyroid37 (3.5)Megestrol0 (0.0)Growth hormone0 (0.0)GastrointestinalProton-pump inhibitors	Androgens	0 (0 0)
Insulin (all types) 40 (3.8) Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Growth hormone 0 (0.0)	Ectrogens with or without progesting	0 (0.0)
Sulfonylureas 20 (1.9) Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Growth hormone 0 (0.0) Gastrointestinal Proton-pump inhibitors	Insulin (all types)	40 (3.8)
Desiccated thyroid 37 (3.5) Megestrol 0 (0.0) Growth hormone 0 (0.0) Gastrointestinal Proton-pump inhibitors	Sulfonvlureas	20 (1 0)
Megestrol 0 (0.0) Growth hormone 0 (0.0) Gastrointestinal Proton-pump inhibitors	Desiccated thyroid	20 (1.2)
Growth hormone 0 (0.0) Gastrointestinal Proton-pump inhibitors	Megestrol	0 (0.0)
Gastrointestinal Proton-pump inhibitors	Growth hormone	0 (0.0)
Proton-pump inhibitors	Gastrointestinal	0 (0.0)
	Proton-nump inhibitors	

Table 5 (continued)

Potentially Inappropriate Medications	Frequency (%)
Esomeprazole	12 (1.1)
Lansoprazole	6 (0.6)
Omeprazole	31 (2.9)
Pantoprazole	65 (6.2)
Rabeprazole	0 (0.0)
Metoclopramide	3 (0.3)
Gl antispasmodics with strong anticholinergic activity	
Clidinium-chlordiazepoxide	1 (0.1)
Dicyclomine	5 (0.5)
Hyoscyamine	3 (0.3)
Scopolamine	0 (0.0)
Mineral oil, given orally	0 (0.0)
Genitourinary	
Desmopressin	0 (0.0)
Pain medications	
Non-COX-2-sective NSAIDs, oral	
Aspirin > 325 mg/day	0 (0.0)
Diclofenac	31 (2.9)
Ibuprofen	27 (2.6)
Indomethacin	3 (0.3)
Ketorolac	0 (0.0)
Meloxicam	49 (4.7)
Naproxen	78 (7.4)
Piroxicam	0 (0.0)
Indomethacin (Suppository)	8 (0.8)
Ketorolac (Parenteral)	23 (2.2)
Skeletal muscle relaxants	
Methocarbamol	32 (3.2)
* alone or in combination with amitriptyline or clidinium	

Adherence to WHO Guidelines

Several discrepancies were observed when comparing prescription patterns with WHO standards. WHO guidelines recommend that no more than three drugs be prescribed per prescription; however, the average prescription in this study contained 4.1 drugs, more than the recommended limit [22]. While this may be necessary for treating multiple chronic conditions, it raises concerns about over-prescription and the risks associated with polypharmacy. Over-prescription can trigger a cascade effect, where the side effects of one medication led to the prescription of additional drugs, complicating treatment and increasing the risk of adverse outcomes [15, 29]. This aligns with findings of Mosleh A and et al. study, in which the average prescription contained 3.6 drugs [32]. Furthermore, the polypharmacy rate in this study (36.2%) is notably higher than those reported in countries such as Argentina (20.5%) [33], Switzerland (17%) [34], and Singapore (14.5%) [35], suggesting either a greater reliance on pharmacological interventions in our study or more complex patient conditions requiring multiple medications.

Despite concerns about polypharmacy, the study revealed some encouraging results in relation to WHO prescribing criteria [22]. The relatively low use of injectable drugs (20.8% of prescriptions) reflects best practices in older adult care, where non-invasive treatments are preferred to minimize risks such as infection and adverse reactions [36]. Additionally, the reduced rate of antibiotic prescribing (only 18.9% of prescriptions included antibiotics) is a positive outcome, well below the national average of 39% in Iran [37, 38]. This indicates a trend toward more conservative antibiotic use, which is critical for preventing the spread of antibiotic resistance [39].

However, the study also identified shortcomings in adherence to WHO recommendations regarding generic prescribing [22]. Although most prescriptions included generic medications, 7.6% did not, representing a missed opportunity for cost-effective treatment. This finding aligns with other studies in Iran, where generic prescribing rates range from 76.8 to 95% [37]. Increasing the use of generics could help reduce the financial burden on older patients and improve medication adherence [40].

Potentially inappropriate medications

One of the most concerning findings of the study is the high frequency of PIMs, with 47.3% of prescriptions containing at least one inappropriate medication. PIMs pose a significant risk to older patients, who are more vulnerable to ADRs and drug interactions due to polypharmacy [41]. The Beers Criteria, which are designed to identify medications that should be avoided in older adults, were not consistently adhered to by prescribers, suggesting a lack of awareness or consideration of these guidelines. As Kargar M and et al. reported a lower PIM rate (31.2%) [27], while studies in Turkey (63.5%) [42], India (65%) [43], and China (64.8%) [44] indicated higher rates, with common PIMs including diuretics, proton pump inhibitors (PPIs), and aspirin [43-45]. The variation in PIM rates across these studies highlights the influence of local prescribing practices and healthcare system differences on PIM use [31].

The frequent prescription of NSAIDs, which accounted for 17.9% of all PIMs, is particularly troubling. Although NSAIDs are effective for pain and inflammation management, their use in older patients carries significant risks, including gastrointestinal bleeding, renal impairment, and cardiovascular complications. This finding points to a gap in the awareness or application of safer alternatives, such as acetaminophen or non-pharmacological interventions like physical therapy [45].

The primary limitation of this study was the absence of access to a comprehensive database of older patients' prescriptions in Yazd City, which would have facilitated a more exhaustive analysis. Additionally, the exclusion of prescription data from other pharmacies within Yazd City, coupled with the relatively short study duration, further restricted the scope of the findings. The lack of information regarding patient comorbidities and the number of concurrent illnesses represents another significant limitation, as this precluded the ability to contextualize prescription patterns and assess potential correlations with the number of medications prescribed.

Furthermore, the study did not account for seasonal variations in prescribing patterns. Although data collection spanned the fall and winter months (October to March), the study was not specifically designed to investigate seasonal fluctuations, particularly in the prescription of antibiotics. Another notable limitation is the potential underestimation of overall medication use due to the analysis being confined to prescribed medications. Over-the-counter (OTC) and nonprescription medications, which are widely utilized by older populations, were not included in the dataset. This omission may result in an incomplete representation of medication use patterns. Future studies should incorporate data on OTC and nonprescription medications to provide a more

comprehensive and accurate assessment of medication use among older patients.

One of the important factors influencing drug prescribing practices in Iran is the challenge of drug importation. Limited access to some drugs, due to sanctions or logistical difficulties, often forces prescribers to substitute internationally recommended drugs with less appropriate or available alternatives. This limitation may inadvertently contribute to the higher prevalence of PIMs and deviations from prescribing guidelines such as the Beers criteria and WHO indicators. Furthermore, inconsistent access to essential drugs can exacerbate polypharmacy as prescribers attempt to compensate for unavailable drugs by combining multiple agents to achieve the desired therapeutic effects [46, 47]. These findings highlight the need for policy interventions that address supply chain challenges to ensure the availability of appropriate drugs.

The findings of this study emphasize the urgent need for more cautious and evidence-based prescribing practices for older patients. Regular medication reviews, ideally conducted by multidisciplinary teams including pharmacists, are essential for identifying unnecessary medications, reducing polypharmacy, and ensuring that PIMs are avoided when safer alternatives exist [48, 49]. Additionally, greater adherence to guidelines such as the Beers Criteria and the integration of these criteria into electronic prescribing systems could reduce prescription errors by flagging potentially inappropriate medications and suggesting safer options.

Future research should examine prescribing trends in both public and private hospital pharmacies to gain a more comprehensive understanding of prescription practices across different healthcare settings.

Conclusions

This study reveals high rates of PIM use and polypharmacy among older patients in Yazd, Iran, with prescribing patterns that do not align with WHO guidelines. These discrepancies pose significant health risks for older patients and underscore the need for a shift in prescribing practices. Physicians must adopt a more judicious approach to medication prescriptions, and pharmacists should play a more active role in ensuring appropriate drug use. Collaboration between doctors and pharmacists, along with patient education about the risks of inappropriate medications, is essential to improving prescription practices and achieving better health outcomes for older patients.

Abbreviations

ADRs	Adverse drug reactions
EDL	Essential Drug List
GPs	General practitioners
NSAIDs	Non-steroidal anti-inflammatory drugs
OTC	Over-the-counter
PIMs	Potentially inappropriate medications

PPIs	Proton pump inhibitors
TCAs	Tricyclic antidepressants
WHO	World Health Organization

Supplementary Information

The online version contains supplementary material available at https://doi.or g/10.1186/s12877-025-05780-5.

Supplementary Material 1

Acknowledgements

The authors sincerely thank the Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran for making this research possible.

Author contributions

G.A. contributed to the design of the work. G.A and S.S. contributed to design methodology of this study. M.M. contributed to data collection. Y.K. and G.A. contributed to data analysis. G.A. and S.S. supervised the project. G.A. and S.S. and Y.K. contributed to Validation and Visualization this study. Y.K. writing the original draft. All authors reviewed the manuscript and approved the submitted version of manuscript.

Funding

This study was conducted financially supported by the Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, with Grant ID: 11437.

Data availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This research was conducted with the approval of the Research Ethics Committee of Shahid Sadoughi University of Medical Sciences, as the code IR.SSU.MEDICINE.REC.1400.163. The committee confirmed that the research adhered to the ethical principles outlined in the 1964 Declaration of Helsinki and its subsequent amendments. Since the data collection relied exclusively on the pharmacy's database and did not involve direct patient interaction, the requirement for informed consent was formally waived by the Research Ethics Committee of Shahid Sadoughi University of Medical Sciences. A certificate of data confidentiality and non-disclosure of patient information was obtained from the researcher. Furthermore, the study involved the participation of the pharmacy's pharmacist, with all necessary permissions obtained, and it was supervised by a clinical pharmacist faculty member.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 13 June 2024 / Accepted: 10 February 2025 Published online: 27 February 2025

References

- Economic UNDo, Division SAP. World Population Ageing, 1950–2050. UN; 2002. p. 81.
- 2. Geriatric health maintenance [Internet]. 2023. Available from https://www.up todate.com/contents/geriatric-health-maintenance#topicContent
- Wickop B, Langebrake C. [Good prescribing practice in the elderly]. Ther Umsch. 2014;71(6):366–73. https://doi.org/10.1024/0040-5930/a000524
- Hedna K, Hakkarainen KM, Gyllensten H, Jonsson AK, Petzold M, Hagg S. Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study. Eur J Clin Pharmacol. 2015;71(12):1525–33. https://doi.org/10.1007/s00228-015-1950-8

- Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: A systematic review and meta-analysis. J Am Pharm Assoc (2003). 2017;57(6):729–38.e10. https://doi.org/10.1016/j.jap h.2017.06.002
- O'Mahony D, Gallagher PF. Inappropriate prescribing in the older population: need for new criteria. Age Ageing. 2008;37(2):138–41. https://doi.org/10.1093 /ageing/afm189
- Hazen ACM, de Bont AA, Boelman L, Zwart DLM, de Gier JJ, de Wit NJ, Bouvy ML. The degree of integration of non-dispensing pharmacists in primary care practice and the impact on health outcomes: a systematic review. Res Social Adm Pharm. 2018;14(3):228–40. https://doi.org/10.1016/j.sapharm.2017.04.01
- Hill-Taylor B, Sketris I, Hayden J, Byrne S, O'Sullivan D, Christie R. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther. 2013;38(5):360–72. https://doi.org/1 0.1111/jcpt.12059
- Reinhild Haerig T, Krause D, Klaassen-Mielke R, Rudolf H, Trampisch HJ, Thuermann P. Potentially inappropriate medication including drug-drug interaction and the risk of frequent falling, hospital admission, and death in older adults - results of a large cohort study (getABI). Front Pharmacol. 2023;14:1062290. https://doi.org/10.3389/fphar.2023.1062290
- Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, Hanlon JT. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370(9582):173–84. https://doi.org/10.1016/S014 0-6736(07)61091-5
- Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J. 2001;31(4):199–205. https://doi.org/10. 1046/j.1445-5994.2001.00044.x
- Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107–16. https://doi.org/10.1001/j ama.289.9.1107
- Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9. https://doi.org/10.1136/bmj.329.745 6.15
- Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. https://doi.org/ 10.1186/s12877-017-0621-2
- Mair AR, Mair AR, Hilmer SN, Kouladjian O'Donnell L. Safe prescribing and monitoring in the older person. Principles and practice of Pharmacovigilance and Drug Safety. Springer; 2024. pp. 459–82.
- Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185–96. https://doi.org/10.1080/14740338.2018.15468 41
- Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65. https://doi.org/10.1517/1474 0338.2013.827660
- Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: evaluating risks and Deprescribing. Am Fam Physician. 2019;100(1):32–8.
- Alldred DP, Kennedy MC, Hughes C, Chen TF, Miller P. Interventions to optimise prescribing for older people in care homes. Cochrane Database Syst Rev. 2016;2(2):CD009095. https://doi.org/10.1002/14651858.CD009095.pub3
- Mekonnen BD, Ayalew MZ, Tegegn AA. Rational drug use evaluation based on World Health Organization Core Drug Use Indicators in Ethiopia: a systematic review. Drug Healthc Patient Saf. 2021;13:159–70. https://doi.org/10.2147 /DHPS.S311926
- By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society. 2023 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–81. h ttps://doi.org/10.1111/jgs.18372
- 22. El Mahalli A. WHO/INRUD drug prescribing indicators at primary health care centres in Eastern province, Saudi Arabia. EMHJ-Eastern Mediterranean Health Journal. 2012;18(11):1091–1096, 2012.
- 23. Aseeri M, Banasser G, Baduhduh O, Baksh S, Ghalibi N. Evaluation of medication error incident reports at a tertiary care hospital. Pharmacy. 2020;8(2):69.
- Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med. 1991;151(9):1825–32.

- Tariq RA, Vashisht R, Sinha A, Scherbak Y. Medication dispensing errors and Prevention. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright. © 2023, StatPearls Publishing LLC.; 2025.
- 26. Goel R, Bhati Y, Dutt H, Chopra V. Prescribing pattern of drugs in the outpatient department of a tertiary care teaching hospital in Ghaziabad, Uttar Pradesh. J Appl Pharm Sci. 2013;3(4):548–51.
- Kargar M, Atrianfar F, Rashidian A, Heidari K, Noroozian M, Gholami K, Javadi MR. Prescribing for geriatrics in Tehran; is it appropriate and rational? Med J Islamic Repub Iran. 2019;33:143.
- Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12(3):443–52. https://doi.org/10.1007/s41999-021-00479-3
- Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162(20):2269–76. https://doi.org/10.1001/archinte.162.20.2269
- Herzog A, Gaertner B, Scheidt-Nave C, Holzhausen M. We can do only what we have the means for 'general practitioners' views of primary care for older people with complex health problems. BMC Fam Pract. 2015;16:1–11.
- 31. Hovstadius B, Petersson G. Factors leading to excessive polypharmacy. Clin Geriatr Med. 2012;28(2):159–72. https://doi.org/10.1016/j.cger.2012.01.001
- Mosleh A, KHOSHNEVIS AS, Sorush M, Eghbalpor A, Babaeian S. Evaluation of the drug prescription status based on the WHO indices in pharmacies of health care centers affiliated to. Tehran University of Medical Sciences; 2011.
- Chiapella LC, Montemarani Menna J, Mamprin ME. Assessment of polypharmacy in elderly patients by using data from dispensed medications in community pharmacies: analysis of results by using different methods of estimation. Int J Clin Pharm. 2018;40(5):987–90. https://doi.org/10.1007/s110 96-018-0663-3
- Blozik E, Rapold R, von Overbeck J, Reich O. Polypharmacy and potentially inappropriate medication in the adult, community-dwelling population in Switzerland. Drugs Aging. 2013;30(7):561–8. https://doi.org/10.1007/s40266-0 13-0073-0
- Tan YW, Suppiah S, Bautista MAC, Malhotra R. Polypharmacy among community-dwelling elderly in Singapore: Prevalence, risk factors and association with medication non-adherence. Proceedings of Singapore Healthcare. 2019;28(4):224–31.
- Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov. 2023;22(5):387–409. https://doi.org/10.1038/s41573-02 3-00670-0
- Ghadimi H, Esmaily HM, Wahlstrom R. General practitioners' prescribing patterns for the elderly in a province of Iran. Pharmacoepidemiol Drug Saf. 2011;20(5):482–7. https://doi.org/10.1002/pds.2106

- Karimi A, Haerizadeh M, Soleymani F, Haerizadeh M, Taheri F. Evaluation of medicine prescription pattern using World Health Organization prescribing indicators in Iran: a cross-sectional study. J Res Pharm Pract. 2014;3(2):39–45. https://doi.org/10.4103/2279-042X.137058
- 39. Colgan R, Powers JH. Appropriate antimicrobial prescribing: approaches that limit antibiotic resistance. Am Family Phys. 2001;64(6):999–1005.
- Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Medication adherence and use of generic drug therapies. Am J Manag Care. 2009;15(7):450–6.
- Alhawassi TM, Alatawi W, Alwhaibi M. Prevalence of potentially inappropriate medications use among older adults and risk factors using the 2015 American Geriatrics Society Beers criteria. BMC Geriatr. 2019;19(1):1–8.
- 42. Albayrak A, Demirbas H. Evaluation of potentially inappropriate medications use and medication complexity in elderly patients applying to community pharmacy in Turkey. BMC Geriatr. 2023;23(1):655. https://doi.org/10.1186/s12 877-023-04381-4
- Anand P, Katyal J, Dey AB, Gupta YK. Characterization of potentially inappropriate medications use in Indian elderly population and their impact on quality of life using Beers criteria. Aging Med (Milton). 2022;5(1):45–52. https:/ /doi.org/10.1002/agm2.12194
- He D, Zhu H, Zhou H, Dong N, Zhang H. Potentially inappropriate medications in Chinese older adults: a comparison of two updated Beers criteria. Int J Clin Pharm. 2021;43(1):229–35. https://doi.org/10.1007/s11096-020-01139-5
- Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of non-steroidal anti-inflammatory drug use in the Elderly. Aging Dis. 2018;9(1):143–50. https://doi.org/10.14336/AD.2017.0306
- Sharifnia SHA, Mohammadzadeh M, Arzani G, Salamzadeh J, Abolfazli SA, Zali A, Khoshdel AR. Main factors affecting Physicians' prescribing decisions: the Iranian experience. Iran J Pharm Res. 2018;17(3):1105–15.
- Zartab S, Koopaei NN, Abbasian H, Koopaei MN, Koopaei NN. The impact of sanction and healthcare system reform on the healthcare performance and pharmaceutical market in Iran; 2001–2016. J Pharm Policy Pract. 2020;13(1):50. https://doi.org/10.1186/s40545-020-00245-z
- Falch C, Alves G. Pharmacists' Role in Older Adults' Medication Regimen Complexity: A Systematic Review. Int J Environ Res Public Health. 2021;18(16). https://doi.org/10.3390/ijerph18168824
- 49. van Mil JF, Schulz M. A review of pharmaceutical care in community pharmacy in Europe. Harv Health Policy Rev. 2006;7(1):155–68.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.